Navigating the FDA 2026 Human Factors Guidance: The Risk-Based Approach
- SANRUBIO, LLC
- Jun 9
- 3 min read
The usability of a medical device is directly tied to its safety. Recognizing the critical impact the device user interface design has on safe and effective use, the FDA issued a finalized guidance document on May 29, 2026, titled "Content of Human Factors Information in Medical Device Marketing Submissions".
This guidance provides a strategic, risk-based framework to guide manufacturers on exactly what human factors information should be included in a marketing submission to the Center for Devices and Radiological Health (CDRH). By submitting the appropriate level of information, manufacturers can improve the efficiency of the FDA review process by reducing the number of requests for additional information.
The Core Concept of Human Factors: Critical Tasks
The foundation of this risk-based approach is the identification of "critical tasks". The FDA defines a critical task as a user task which, if performed incorrectly or not performed at all, would or could cause serious harm to the patient or user, including compromised medical care.
The 3 HF Submission Categories
The FDA has categorized marketing submissions into three tiers based on device modifications and the use-related risk analysis (URRA):
HF Submission Category 1: This applies to modifications to an existing device where there is no change to the user interface, intended device users, intended device uses, intended use environment(s), training, or labeling . Manufacturers only need to provide a conclusion and a high-level summary justifying that the modifications do not affect the human factors considerations.
HF Submission Category 2: This applies when a new device has no critical tasks, or when a modified device introduces no new critical tasks and existing critical tasks are not impacted . It also applies if critical tasks exist, but human factors validation test data is deemed unnecessary based on considerations like the user interface history of use, complexity, and the adequacy of existing risk control measures . The submission must include a detailed rationale supporting this decision.
HF Submission Category 3: This category is for devices where human factors validation test data must be submitted . This includes comprehensive Human Factors Engineering/Usability Engineering (HFE/UE) reports with validation testing addressing critical tasks . This is typically needed for complex user interfaces or if the device type historically has been associated with known use error issues.
Conclusion
The May 2026 FDA guidance removes the guesswork from human factors reporting. Manufacturers must remember that under the Quality Management System Regulation (QMSR), they are required to verify and validate device design and document these activities in their design and development files (ISO 13485:2016 Subclause 7.3), regardless of whether all that data is submitted to the FDA. Accurately determining your HF Submission Category is the first strategic step toward a faster, more predictable clearance.
At Sanrubio, LLC, strategically supporting manufacturers from the U.S., Latin America, Europe, and Asia, we offer:
Medical Device Establishment Registration Renewal
Personalized regulatory advice: from Pre-Submission design to 510(k) submission (Pre-market notification), De Novo Devices submission, and QMSR consulting.
Strategic location: in Miami, key hub for foreign manufacturers entering the U.S. market.
Free initial consultancy: analyze your case with us and optimize your regulatory strategy.
Ready to bring your Medical Devices to the U.S. market?
Contact us for a free personalized consult and move ahead with confidence in your regulatory journey.
Comments